Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Profit After Tax (2021 - 2025)

Historic Profit After Tax for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to -$31.5 million.

  • Aligos Therapeutics' Profit After Tax fell 6375.2% to -$31.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.5 million, marking a year-over-year decrease of 1235.69%. This contributed to the annual value of -$131.2 million for FY2024, which is 4964.93% down from last year.
  • As of Q3 2025, Aligos Therapeutics' Profit After Tax stood at -$31.5 million, which was down 6375.2% from -$15.9 million recorded in Q2 2025.
  • Aligos Therapeutics' 5-year Profit After Tax high stood at $43.1 million for Q1 2025, and its period low was -$82.1 million during Q4 2024.
  • Its 5-year average for Profit After Tax is -$23.6 million, with a median of -$23.0 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Aligos Therapeutics' Profit After Tax was 22359.23% (2025), while the steepest drop was 41343.61% (2025).
  • Aligos Therapeutics' Profit After Tax (Quarter) stood at -$37.7 million in 2021, then skyrocketed by 41.97% to -$21.9 million in 2022, then decreased by 27.44% to -$27.9 million in 2023, then crashed by 194.53% to -$82.1 million in 2024, then skyrocketed by 61.61% to -$31.5 million in 2025.
  • Its last three reported values are -$31.5 million in Q3 2025, -$15.9 million for Q2 2025, and $43.1 million during Q1 2025.